Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer

por Flores, L M, Kindelberger, D W, Ligon, A H, Capelletti, M, Fiorentino, M, Loda, M, Cibas, E S, Jänne, P A, Krop, I E
Publicado 2010

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells

por Tanizaki, J, Okamoto, I, Takezawa, K, Sakai, K, Azuma, K, Kuwata, K, Yamaguchi, H, Hatashita, E, Nishio, K, Janne, P A, Nakagawa, K
Publicado 2012

Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results fro...

por Planchard, D., Feng, P.-H., Karaseva, N., Kim, S.-W., Kim, T.M., Lee, C.K., Poltoratskiy, A., Yanagitani, N., Marshall, R., Huang, X., Howarth, P., Jänne, P.A., Kobayashi, K.
Publicado 2021

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

por Cappuzzo, F, Varella-Garcia, M, Finocchiaro, G, Skokan, M, Gajapathy, S, Carnaghi, C, Rimassa, L, Rossi, E, Ligorio, C, Di Tommaso, L, Holmes, A J, Toschi, L, Tallini, G, Destro, A, Roncalli, M, Santoro, A, Jänne, P A
Publicado 2008

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients

por Koivunen, J P, Kim, J, Lee, J, Rogers, A M, Park, J O, Zhao, X, Naoki, K, Okamoto, I, Nakagawa, K, Yeap, B Y, Meyerson, M, Wong, K-K, Richards, W G, Sugarbaker, D J, Johnson, B E, Jänne, P A
Publicado 2008

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

por Jänne, P A, Smith, I, McWalter, G, Mann, H, Dougherty, B, Walker, J, Orr, M C M, Hodgson, D R, Shaw, A T, Pereira, J R, Jeannin, G, Vansteenkiste, J, Barrios, C H, Franke, F A, Crinò, L, Smith, P
Publicado 2015

SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced o...

por Soria, J -C, Fülöp, A, Maciel, C, Fischer, J R, Girotto, G, Lago, S, Smit, E, Ostoros, G, Eberhardt, W E E, Lishkovska, P, Lovick, S, Mariani, G, McKeown, A, Kilgour, E, Smith, P, Bowen, K, Kohlmann, A, Carlile, D J, Jänne, P A
Publicado 2017

Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer

por Vaishnavi, A., Capelletti, M., Le, A.T., Kako, S., Butaney, M., Ercan, D., Mahale, S., Davies, K.D., Aisner, D.L., Pilling, A.B., Berge, E.M., Kim, J., Sasaki, H., Park, S., Kryukov, G., Garraway, L.A., Hammerman, Peter S., Haas, J., Andrews, S.W., Lipson, D., Stephens, P.J., Miller, V.A., Varella-Garcia, M., Jänne, P.A., Doebele, R.C.
Publicado 2013